{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:58:47Z","timestamp":1785859127894,"version":"3.56.0"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1097\/01.bor.0000197995.27579.9b","type":"journal-article","created":{"date-parts":[[2005,12,12]],"date-time":"2005-12-12T04:01:29Z","timestamp":1134360089000},"page":"3-9","source":"Crossref","is-referenced-by-count":62,"title":["New approaches in the treatment of Adamantiades-Beh\u00e7et's disease"],"prefix":"10.1097","volume":"18","author":[{"given":"Nicol\u00f2","family":"Pipitone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazio","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Cantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Triolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"Suppl 36","key":"R1-3-20210128","first-page":"S46","article-title":"Clinical manifestations of Behcet's disease in 137 Italian patients: results of a multicenter study","volume":"22","author":"Pipitone","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"R2-3-20210128","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","article-title":"The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center","volume":"82","author":"Kural-Seyahi","year":"2003","journal-title":"Medicine (Baltimore)"},{"issue":"Suppl 30","key":"R3-3-20210128","first-page":"S44","article-title":"The role of heat shock proteins in Behcet's disease","volume":"21","author":"Direskeneli","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"R4-3-20210128","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/art.1780380321","article-title":"Excessive function of peripheral blood neutrophils from patients with Behcet's disease and from HLA-B51 transgenic mice","volume":"38","author":"Takeno","year":"1995","journal-title":"Arthritis Rheum"},{"key":"R5-3-20210128","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/immu.200390025","article-title":"Prevention of mucosally induced uveitis with a HSP60-derived peptide linked to cholera toxin B subunit","volume":"33","author":"Phipps","year":"2003","journal-title":"Eur J Immunol"},{"key":"R6-3-20210128","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2249.2004.02520.x","article-title":"Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease","volume":"137","author":"Stanford","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"R7-3-20210128","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","article-title":"A controlled trial of azathioprine in Behcet's syndrome","volume":"322","author":"Yazici","year":"1990","journal-title":"N Engl J Med"},{"key":"R8-3-20210128","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/art.1780400425","article-title":"Azathioprine in Behcet's syndrome: effects on long-term prognosis","volume":"40","author":"Hamuryudan","year":"1997","journal-title":"Arthritis Rheum"},{"key":"R9-3-20210128","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1076\/ocii.9.4.219.3957","article-title":"Short-term chlorambucil for refractory uveitis in Behcet's disease","volume":"9","author":"Mudun","year":"2001","journal-title":"Ocul Immunol Inflamm"},{"key":"R10-3-20210128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0002-9343(84)90753-8","article-title":"Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet's disease","volume":"76","author":"O'Duffy","year":"1984","journal-title":"Am J Med"},{"key":"R11-3-20210128","first-page":"136","article-title":"Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome","volume":"20","author":"BenEzra","year":"1988","journal-title":"Transplant Proc"},{"key":"R12-3-20210128","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/archneur.1989.00520390031011","article-title":"Neurologic involvement in Behcet's syndrome: a prospective study","volume":"46","author":"Serdaroglu","year":"1989","journal-title":"Arch Neurol"},{"key":"R13-3-20210128","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","article-title":"Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease","volume":"1","author":"Masuda","year":"1989","journal-title":"Lancet"},{"key":"R14-3-20210128","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","article-title":"A double-blind trial of colchicine in Behcet's syndrome","volume":"44","author":"Yurdakul","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R15-3-20210128","first-page":"399","article-title":"A double blind study of colchicine in Behcet's disease","volume":"65","author":"Aktulga","year":"1980","journal-title":"Haematologica"},{"key":"R16-3-20210128","first-page":"1365","article-title":"Recurrent aphthous stomatitis: treatment with colchicines: an open trial of 54 cases [in French]","volume":"129","author":"Fontes","year":"2002","journal-title":"Ann Dermatol Venereol"},{"key":"R17-3-20210128","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1346-8138.2002.tb00263.x","article-title":"Dapsone in Behcet's disease: a double-blind, placebo-controlled, cross-over study","volume":"29","author":"Sharquie","year":"2002","journal-title":"J Dermatol"},{"key":"R18-3-20210128","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.survophthal.2005.04.009","article-title":"Current concepts in the etiology and treatment of Behcet disease","volume":"50","author":"Evereklioglu","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"R19-3-20210128","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-510X(98)00165-8","article-title":"Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease","volume":"159","author":"Hirohata","year":"1998","journal-title":"J Neurol Sci"},{"key":"R20-3-20210128","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","article-title":"Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome: a randomized, double-blind, placebo-controlled trial","volume":"128","author":"Hamuryudan","year":"1998","journal-title":"Ann Intern Med"},{"key":"R21-3-20210128","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF00407749","article-title":"Behcet's syndrome: treatment with recombinant leukocyte alpha-interferon","volume":"278","author":"Tsambaos","year":"1986","journal-title":"Arch Dermatol Res"},{"key":"R22-3-20210128","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/rheumatology\/keh311","article-title":"Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease","volume":"43","author":"Treusch","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"R23-3-20210128","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1365-2249.1992.tb06470.x","article-title":"Interferon-alpha and dexamethasone inhibit adhesion of T cells to endothelial cells and synovial cells","volume":"88","author":"Eguchi","year":"1992","journal-title":"Clin Exp Immunol"},{"key":"R24-3-20210128","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1067\/mjd.2001.117728","article-title":"HSP 60 expression in mucocutaneous lesions of Behcet's disease","volume":"45","author":"Ergun","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"R25-3-20210128","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1067\/mlc.2003.1","article-title":"Expansion of gammadelta T-cells in Behcet's disease: role of disease activity and microbial flora in oral ulcers","volume":"141","author":"Bank","year":"2003","journal-title":"J Lab Clin Med"},{"key":"R26-3-20210128","doi-asserted-by":"crossref","first-page":"R262","DOI":"10.1186\/ar785","article-title":"Vgamma9\/Vdelta2 T lymphocytes in Italian patients with Behcet's disease: evidence for expansion, and tumour necrosis factor receptor II and interleukin-12 receptor beta1 expression in active disease","volume":"5","author":"Triolo","year":"2003","journal-title":"Arthritis Res Ther"},{"key":"R27-3-20210128","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2249.1997.274-ce1159.x","article-title":"Role of gammadelta T lymphocytes in the development of Behcet's disease","volume":"107","author":"Yamashita","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"R28-3-20210128","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1073\/pnas.93.6.2272","article-title":"Gamma\/delta and other unconventional T lymphocytes: what do they see and what do they do?","volume":"93","author":"Kaufmann","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R29-3-20210128","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1046\/j.1365-2559.2000.00859.x","article-title":"Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behcet disease","volume":"36","author":"Kobayashi","year":"2000","journal-title":"Histopathology"},{"key":"R30-3-20210128","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(99)05131-4","article-title":"Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behcet's disease: a randomised trial","volume":"355","author":"Demiroglu","year":"2000","journal-title":"Lancet"},{"key":"R31-3-20210128","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","article-title":"Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis","volume":"87","author":"Kotter","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"R32-3-20210128","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.semarthrit.2003.09.005","article-title":"Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial","volume":"33","author":"Kotter","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"R33-3-20210128","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00347-003-0927-7","article-title":"Ocular involvement in Behcet's disease: first 5-year results for visual development after treatment with interferon alfa-2a nach [in German]","volume":"101","author":"Deuter","year":"2004","journal-title":"Ophthalmologe"},{"key":"R34-3-20210128","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/ard.62.5.492","article-title":"Effects of interferon alpha treatment on the clinical course of refractory Behcet's disease: an open study","volume":"62","author":"Calguneri","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R35-3-20210128","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","article-title":"The use of interferon alpha in Behcet disease: review of the literature","volume":"33","author":"Kotter","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"R36-3-20210128","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000055677","article-title":"Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis","volume":"33","author":"Santos","year":"2001","journal-title":"Ophthalmic Res"},{"key":"R37-3-20210128","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cyto.2003.09.003","article-title":"Cytokine production profile in patients with Behcet's disease treated with infliximab","volume":"24","author":"Misumi","year":"2003","journal-title":"Cytokine"},{"key":"R38-3-20210128","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/08830180212067","article-title":"Bench to bedside: new approaches to the immunotherapy of uveitic disease","volume":"21","author":"Nussenblatt","year":"2002","journal-title":"Int Rev Immunol"},{"key":"R39-3-20210128","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.berh.2004.02.008","article-title":"Behcet's disease","volume":"18","author":"Marshall","year":"2004","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R40-3-20210128","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/bjo.2003.037192","article-title":"Anti-TNF-alpha therapy for sight threatening uveitis","volume":"89","author":"Lindstedt","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R41-3-20210128","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis","volume":"31","author":"Ohno","year":"2004","journal-title":"J Rheumatol"},{"issue":"Suppl 30","key":"R42-3-20210128","first-page":"S57","article-title":"Intra-articular anti-tumor necrosis factor alpha antibody in recalcitrant arthritis of Behcet's disease","volume":"21","author":"Andonopoulos","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"R43-3-20210128","first-page":"181","article-title":"Successful treatment of long-standing neuro-Behcet's disease with infliximab","volume":"32","author":"Sarwar","year":"2005","journal-title":"J Rheumatol"},{"key":"R44-3-20210128","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/ard.62.3.280","article-title":"Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behcet's syndrome","volume":"62","author":"Licata","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R45-3-20210128","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.bor.0000149084.16639.b0","article-title":"Endothelial cell dysfunction in systemic vasculitis: new developments and therapeutic prospects","volume":"17","author":"Bacon","year":"2005","journal-title":"Curr Opin Rheumatol"},{"key":"R46-3-20210128","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1172\/JCI19284","article-title":"Antithrombotic activity of TNF-alpha","volume":"112","author":"Cambien","year":"2003","journal-title":"J Clin Invest"},{"key":"R47-3-20210128","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","article-title":"Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease","volume":"140","author":"Sfikakis","year":"2004","journal-title":"Ann Intern Med"},{"key":"R48-3-20210128","first-page":"98","article-title":"Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J Rheumatol"},{"key":"R49-3-20210128","first-page":"1078","article-title":"Criteria for diagnosis of Behcets disease.","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"R50-3-20210128","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.semarthrit.2005.01.003","article-title":"Differentiating the efficacy of the tumor necrosis factor inhibitors","volume":"34","author":"Haraoui","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"R52-3-20210128","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s10238-004-0033-4","article-title":"Behcet's disease","volume":"4","author":"Suzuki","year":"2004","journal-title":"Clin Exp Med"},{"key":"R53-3-20210128","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/rheumatology\/41.10.1213-c","article-title":"Behcet's syndrome: response to infliximab after failure of etanercept","volume":"41","author":"Estrach","year":"2002","journal-title":"Rheumatology (Oxford)"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001665-201203000-00083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:05:07Z","timestamp":1785855907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002281-200601000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.bor.0000197995.27579.9b","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}